Advertisement

Optimal Imaging Surveillance Schedules after Liver-Directed Therapy for Hepatocellular Carcinoma

Published:November 04, 2014DOI:https://doi.org/10.1016/j.jvir.2014.09.013

      Abstract

      Purpose

      To optimize surveillance schedules for the detection of recurrent hepatocellular carcinoma (HCC) after liver-directed therapy.

      Materials and Methods

      New methods have emerged that allow quantitative analysis and optimization of surveillance schedules for diseases with substantial rates of recurrence such as HCC. These methods were applied to 1,766 consecutive chemoembolization, radioembolization, and radiofrequency ablation procedures performed on 910 patients between 2006 and 2011. Computed tomography or magnetic resonance imaging performed just before repeat therapy was set as the time of “recurrence,” which included residual and locally recurrent tumor as well as new liver tumors. Time-to-recurrence distribution was estimated by Kaplan–Meier method. Average diagnostic delay (time between recurrence and detection) was calculated for each proposed surveillance schedule using the time-to-recurrence distribution. An optimized surveillance schedule could then be derived to minimize the average diagnostic delay.

      Results

      Recurrence is 6.5 times more likely in the first year after treatment than in the second. Therefore, screening should be much more frequent in the first year. For eight time points in the first 2 years of follow-up, the optimal schedule is 2, 4, 6, 8, 11, 14, 18, and 24 months. This schedule reduces diagnostic delay compared with published schedules and is cost-effective.

      Conclusions

      The calculated optimal surveillance schedules include shorter-interval follow-up when there is a higher probability of recurrence and longer-interval follow-up when there is a lower probability. Cost can be optimized for a specified acceptable diagnostic delay or diagnostic delay can be optimized within a specified acceptable cost.

      Abbreviations:

      HCC (hepatocellular carcinoma), RF (radiofrequency)
      To read this article in full you will need to make a payment
      SIR Member Login
      Society Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Purchase one-time access:

      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Llovet J.M.
        • Ducreux M.
        EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.
        J Hepatol. 2012; 56: 908-943
        • Santi V.
        • Trevisani F.
        • Gramenzi A.
        • et al.
        Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival.
        J Hepatol. 2010; 53: 291-297
        • Kantrowitz M.
        • inventor; MK Consulting, Inc., assignee
        System for minimizing the cost and maximizing the effectiveness of monitoring for recurrence of a condition.
        US Patent 7,778,847. 2010; (2010 Aug 17)
        • Lim H.K.
        • Choi D.
        • Lee W.J.
        • et al.
        Hepatocellular carcinoma treated with percutaneous radio-frequency ablation: evaluation with follow-up multiphase helical CT.
        Radiology. 2001; 221: 447-454
        • Lewandowski R.J.
        • Kulik L.M.
        • Riaz A.
        • et al.
        A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization.
        Am J Transplant. 2009; 9: 1920-1928
        • Rhee T.K.
        • Naik N.K.
        • Deng J.
        • et al.
        Tumor response after yttrium-90 radioembolization for hepatocellular carcinoma: comparison of diffusion-weighted functional MR imaging with anatomic MR imaging.
        J Vasc Interv Radiol. 2008; 19: 1180-1196
        • Ha B.Y.
        • Ahmed A.
        • Sze D.Y.
        • et al.
        Long-term survival of patients with unresectable hepatocellular carcinoma treated with transcatheter arterial chemoinfusion.
        Aliment Pharmacol Ther. 2007; 26: 839-846
        • Kirch R.L.A.
        • Klein M.
        Surveillance schedules for medical examinations.
        Manage Sci. 1974; 20: 1403-1409
        • Press W.H.
        • Teukolsky S.A.
        • Vetterling W.T.
        • Flannery B.P.
        Numerical Recipes: The Art of Scientific Computing.
        3rd ed. Cambridge University Press, New York2007
        • Andersson K.L.
        • Salomon J.A.
        • Goldie S.J.
        • Chung R.T.
        Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis.
        Clin Gastroenterol Hepatol. 2008; 6: 1418-1424
      1. Centers for Medicare and Medicaid Services. Physician fee schedule search. Available at http://www.cms.gov/apps/physician-fee-schedule/search/search-criteria.aspx. Accessed February 17, 2014.

        • Min J.H.
        • Lee M.W.
        • Rhim H.
        • et al.
        Recurrent hepatocellular carcinoma after transcatheter arterial chemoembolization: planning sonography for radiofrequency ablation.
        J Ultras Med. 2011; 30: 617-624
        • Dai X.
        • Han M.J.
        • Su H.Y.
        • et al.
        Study of recurrence and metastatic patterns of hepatic cellular carcinoma after transcatheter arterial chemoembolization.
        J Chin Clin Med Imaging. 2004; 15: 613-615